Summit Therapeutics (SMMT) Capital Expenditures Growth (5y) (2024 - 2026)

Summit Therapeutics (SMMT) Capital Expenditures Growth (5y) (2024 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Summit Therapeutics 10.29 Bn 9.60 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2026 7.52%
Mar 31, 2026 92.32%
Dec 31, 2025 -139.88%
Sep 30, 2025 32.20%
Jun 30, 2025 77.19%
Mar 31, 2025 116.26%
Dec 31, 2024 80.96%
Mar 31, 2024 -99.19%